Loading...
•
Dec 31, 2021
Tenaya Therapeutics Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Key Takeaways
Tenaya Therapeutics reported its Q4 and full year 2021 financial results, highlighting progress in research, preclinical development, manufacturing, and corporate operations. The company is advancing three therapeutic candidates towards clinical trials and strengthening its leadership team.
TN-201 IND application expected to be submitted to the FDA in the second half of 2022.
TN-301 IND application expected to be submitted to the FDA in the second half of 2022.
TN-401 IND application expected to be submitted to the FDA in 2023.
cGMP manufacturing facility expected to be operational in the first half of 2022.
Tenaya Therapeutics
Tenaya Therapeutics
Forward Guidance
Tenaya Therapeutics anticipates continued progress in advancing its therapeutic candidates towards clinical trials and strengthening its manufacturing and clinical development capabilities. The company expects its cash reserves to be sufficient to fund operations into the second half of 2023.
Positive Outlook
- TN-201 IND application submission expected in the second half of 2022
- TN-301 IND application submission expected in the second half of 2022
- TN-401 IND application submission expected in 2023
- cGMP manufacturing facility expected to be operational in the first half of 2022
- Cash reserves expected to fund operations into the second half of 2023
Challenges Ahead
- Risks associated with discovering, developing, and commercializing drugs
- Uncertainties regarding preclinical studies and clinical trials
- Potential impacts of the COVID-19 pandemic on manufacturing and operations
- Risk of clinical trial results differing from expectations
- Reliance on third parties